Company News
Translumina Launches SPARX Trial Enrolling 1,380 Patients
Translumina Therapeutics initiates the multinational SPARX RCT comparing a drug‑coated balloon first strategy with contemporary drug‑eluting stents in complex coronary disease.
The trial will enroll 1
